2018 한국형 공황장애 치료지침서 : 초기 및 유지 약물치료 전략
Korean Guidelines for the Treatment of Panic Disorder 2018 : Initial and Maintenance Treatment Strategies for the Pharmacological Treatment of Panic Disorder
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Objective : The Korean Association of Anxiety Disorders developed Korean guidelines for treatment of panic disorder (PD) 2018. In this paper, we discussed the consensus among psychiatrists, regarding initial and maintenance treatment strategies for pharmacological treatment of PD in Korea. Methods : Based on current treatment guidelines published by the American Psychiatric Association, the National Institute for Clinical Excellence, and the Canadian Psychiatric Association, we developed questionnaires pertinent to initial and maintenance treatment strategies for pharmacological treatment of PD. Seventy-two experts in PD answered questionnaires. We classified expert opinions into three categories, first, second, and third-line treatment strategies, by analyzing the 95% confidence interval. Results : Antidepressants, benzodiazepine anxiolytics, and cognitive-behavioral therapy (CBT) were recommended as treatments of choice (ToC), and first-line strategies for initial treatment of PD. Escitalopram, paroxetine, sertraline, and venlafaxine were preferred from among many anti-panic drugs. Mean starting dose of anti-panic drugs for initial treatment of PD was relatively lower, than that for other psychiatric illnesses such as major depressive disorder. In the case of maintenance treatment of PD, antidepressants and CBT were selected as ToC and first-line strategies. Patients were typically examined every four weeks during treatment, to review effectiveness and side effects of the drug. Pharmacotherapy was generally continued for one year or more. Conclusion : This study provides information about consensus among Korean experts regarding pharmacological treatment strategies for patients with panic disorder. (Anxiety and Mood 2018;14(2):53-62)
Abstract
Objective : The Korean Association of Anxiety Disorders developed Korean guidelines for treatment of panic disorder (PD) 2018. In this paper, we discussed the consensus among psychiatrists, regarding initial and maintenance treatment strategies for pharmacological treatment of PD in Korea. Methods : Based on current treatment guidelines published by the American Psychiatric Association, the National Institute for Clinical Excellence, and the Canadian Psychiatric Association, we developed questionnaires pertinent to initial and maintenance treatment strategies for pharmacological treatment of PD. Seventy-two experts in PD answered questionnaires. We classified expert opinions into three categories, first, second, and third-line treatment strategies, by analyzing the 95% confidence interval. Results : Antidepressants, benzodiazepine anxiolytics, and cognitive-behavioral therapy (CBT) were recommended as treatments of choice (ToC), and first-line strategies for initial treatment of PD. Escitalopram, paroxetine, sertraline, and venlafaxine were preferred from among many anti-panic drugs. Mean starting dose of anti-panic drugs for initial treatment of PD was relatively lower, than that for other psychiatric illnesses such as major depressive disorder. In the case of maintenance treatment of PD, antidepressants and CBT were selected as ToC and first-line strategies. Patients were typically examined every four weeks during treatment, to review effectiveness and side effects of the drug. Pharmacotherapy was generally continued for one year or more. Conclusion : This study provides information about consensus among Korean experts regarding pharmacological treatment strategies for patients with panic disorder. (Anxiety and Mood 2018;14(2):53-62)
참고문헌 (26)
- Doyle A, "Long-term management of panic disorder", J Clin Psychiatry, 65(Suppl 5), pp.24~28 (2004)
- Katon W, "Panic disorder: epidemiology, diagnosis, and treatment in primary care", J Clin Psychiatry, 47(Suppl), pp.21~30 (1986)
- Batelaan NM, "Evidence-based pharmacotherapy of panic disorder: an update", Int J Neuropsychopharmacol, 15, pp.403~415 (2012)
- Liebowitz MR, "Panic disorder as a chronic illness", J Clin Psychiatry, 58(Suppl 13), pp.5~8 (1997)
- Zamorski MA, "What to do when SSRIs fail: eight strategies for optimizing treatment of panic disorder", Am Fam Physician, 66, pp.1477~1484 (2002)
- Slaap BR, "The prediction of nonresponse to pharmacotherapy in panic disorder: a review", Depress Anxiety, 14, pp.112~122 (2001)
- Katschnig H, "The long-term course of panic disorder and its predictors", J Clin Psychopharmacol, 18, pp.6S~11S (1998)
- Marchesi C, "Pharmacological management of panic disorder", Neuropsychiatr Dis Treat, 4, pp.93~106 (2008)
- Mitte K, "A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia", J Affect Disord, 88, pp.27~45 (2005)
- Bakker A, "Evidence-based pharmacotherapy of panic disorder", Int J Neuropsychopharmacol, 8, pp.473~482 (2005)
- Practice guideline for the treatment of patients with panic disorder, "Work Group on Panic Disorder", American Psychiatric Association. Am J Psychiatry, 155, pp.1~34 (1998)
- Katzman MA, "Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders", BMC Psychiatry, 14(Suppl 1), pp.S1~ (2014)
- American Psychiatric Association, "Practice guideline for the Treatment of Patients with Panic Disorder", ~ (2010)
- Baldwin DS, "Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 19, pp.567~596 (2005)
- Baldwin DS, "Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology", J Psychopharmacol, 28, pp.403~439 (2014)
- Executive Committee for Korean Medication Algorithm for Panic Disorder, "Korean medication algorithm project for panic disorder 2008" (2008), ML Communication
- Executive Committee for Korean Treatment Guideline for Panic Disorder, "Korean guidelines for the treatment of panic disorder 2018" (2018), Eims International
- Panic disorder overview, "National Institute for Health and Care Excellence", ~ (2016)
- National Institute for Health and Care Excellence, "Generalised anxiety disorder and panic disorder in adults: Management", ~ (2011)
- Andrisano C, "Newer antidepressants and panic disorder: a meta-analysis", Int Clin Psychopharmacol, 28, pp.33~45 (2013)
- Gorman JM, "The use of newer antidepressants for panic disorder", J Clin Psychiatry, 58(Suppl 14), pp.54~58 (1997)
- Montgomery S, "Efficacy of escitalopram compared to citalopram: a meta-analysis", Int J Neuropsychopharmacol, 14, pp.261~268 (2011)
- American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders (DSM-5)", ~ (2013)
- Susman J, "The Role of High-Potency Benzodiazepines in the Treatment of Panic Disorder", Prim Care Companion J Clin Psychiatry, 7, pp.5~11 (2005)
- Sheehan DV, "Benzodiazepines in panic disorder and agoraphobia", J Affect Disord, 13, pp.169~181 (1987)
- Bruce SE, "Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia", Am J Psychiatry, 160, pp.1432~1438 (2003)